A Case of Uterine Lymphangioleiomyomatosis Complicated by Tuberous Sclerosis Complex.

IF 0.6 Q4 OBSTETRICS & GYNECOLOGY
Kaori Yamada, Yukio Yamanishi, Junichi Aratake, Nanayo Sasagasako, Yoshihide Inayama, Rei Gou, Atsuko Kawamura, Megumi Yamanishi, Kenzo Kosaka
{"title":"A Case of Uterine Lymphangioleiomyomatosis Complicated by Tuberous Sclerosis Complex.","authors":"Kaori Yamada,&nbsp;Yukio Yamanishi,&nbsp;Junichi Aratake,&nbsp;Nanayo Sasagasako,&nbsp;Yoshihide Inayama,&nbsp;Rei Gou,&nbsp;Atsuko Kawamura,&nbsp;Megumi Yamanishi,&nbsp;Kenzo Kosaka","doi":"10.1155/2022/2893975","DOIUrl":null,"url":null,"abstract":"<p><p>Lymphangioleiomyomatosis (LAM) is one of the presentations of perivascular epithelioid cell neoplasm that is frequently complicated by tuberous sclerosis complex (TSC). Here, we report an uncommon case of uterine LAM treated with everolimus, which is a mechanistic target of rapamycin (mTOR) inhibitor. A 42-year-old female patient (gravida 0) with a history of TSC presented with abdominal pain. Pelvic magnetic resonance imaging showed multiple masses in the uterine myometrium, suggesting tumors that may contain internal hemorrhagic components. The lesions were suspected as the root cause of her symptoms. After everolimus was administered for a previously diagnosed renal angiolipoma, her uterine tumors temporarily decreased in size. Subsequently, laparoscopic hysterectomy and bilateral salpingectomy were performed since she could not tolerate everolimus for a long period due to the medication's side effects. Furthermore, the patient was diagnosed with LAM through histopathological examination after surgical resection. Therefore, it is advisable to suspect and investigate uterine LAM when a patient with a history of TSC presents with irregular genital bleeding or abdominal pain. Moreover, mTOR inhibitors may be a treatment option, in addition to surgery, in cases of uterine LAM exacerbation.</p>","PeriodicalId":9610,"journal":{"name":"Case Reports in Obstetrics and Gynecology","volume":"2022 ","pages":"2893975"},"PeriodicalIF":0.6000,"publicationDate":"2022-01-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9767712/pdf/","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Case Reports in Obstetrics and Gynecology","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1155/2022/2893975","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q4","JCRName":"OBSTETRICS & GYNECOLOGY","Score":null,"Total":0}
引用次数: 0

Abstract

Lymphangioleiomyomatosis (LAM) is one of the presentations of perivascular epithelioid cell neoplasm that is frequently complicated by tuberous sclerosis complex (TSC). Here, we report an uncommon case of uterine LAM treated with everolimus, which is a mechanistic target of rapamycin (mTOR) inhibitor. A 42-year-old female patient (gravida 0) with a history of TSC presented with abdominal pain. Pelvic magnetic resonance imaging showed multiple masses in the uterine myometrium, suggesting tumors that may contain internal hemorrhagic components. The lesions were suspected as the root cause of her symptoms. After everolimus was administered for a previously diagnosed renal angiolipoma, her uterine tumors temporarily decreased in size. Subsequently, laparoscopic hysterectomy and bilateral salpingectomy were performed since she could not tolerate everolimus for a long period due to the medication's side effects. Furthermore, the patient was diagnosed with LAM through histopathological examination after surgical resection. Therefore, it is advisable to suspect and investigate uterine LAM when a patient with a history of TSC presents with irregular genital bleeding or abdominal pain. Moreover, mTOR inhibitors may be a treatment option, in addition to surgery, in cases of uterine LAM exacerbation.

Abstract Image

Abstract Image

Abstract Image

子宫淋巴管平滑肌瘤病合并结节性硬化症1例。
淋巴管平滑肌瘤病(LAM)是血管周围上皮样细胞肿瘤的表现之一,常并发结节性硬化症(TSC)。在此,我们报告一例罕见的子宫LAM用依维莫司治疗,依维莫司是雷帕霉素(mTOR)抑制剂的机制靶点。42岁女性患者(妊娠0岁),有TSC病史,表现为腹痛。盆腔磁共振成像显示子宫肌层多发肿块,提示肿瘤可能含有内出血成分。这些病变被怀疑是她症状的根本原因。依维莫司治疗先前诊断的肾血管脂肪瘤后,她的子宫肿瘤暂时缩小。由于依维莫司的副作用,患者不能长期耐受,随后行腹腔镜子宫切除术和双侧输卵管切除术。手术切除后经组织病理学检查诊断为LAM。因此,当有TSC病史的患者出现不规则生殖器出血或腹痛时,建议怀疑和调查子宫LAM。此外,mTOR抑制剂可能是一种治疗选择,除了手术,在子宫LAM恶化的情况下。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Case Reports in Obstetrics and Gynecology
Case Reports in Obstetrics and Gynecology Medicine-Obstetrics and Gynecology
CiteScore
1.30
自引率
0.00%
发文量
64
审稿时长
12 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信